Ligelizumab

Drug Profile

Ligelizumab

Alternative Names: QGE-031

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Tanox
  • Developer Novartis
  • Class Allergens; Antiallergics; Antiasthmatics; Food allergy immunotherapies; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action IgE receptor antagonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Allergic asthma; Bullous pemphigoid; Urticaria
  • Phase I Hypersensitivity
  • Suspended Atopic dermatitis

Most Recent Events

  • 05 Apr 2017 Novartis plans regulatory filings for Urticaria in 2020
  • 14 Mar 2017 Novartis terminates a phase II extension trial for Allergic asthma USA, Argentina, Canada, Israel, South Korea, South Africa, Mexico, Russia, Turkey, the Czech Republic, Finland, France, Germany, Hungary, Italy, Poland, Portugal, Romania, Slovakia and United Kingdom(NCT02075008)
  • 01 Mar 2016 Novartis Pharmaceuticals initiates enrolment in a phase II extension study for Urticaria in USA (NCT02649218)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top